Dynamic Changes of Peripheral NK Cells Predict Outcome in Patients with PD-L1 Positive Non-small-cell Lung Cancer Undergoing Immune Checkpoint Inhibitors as Second-line Therapy

References

• Hanna NH, Robinson AG, Temin S, Baker S Jr, Brahmer JR, Ellis PM, et al. Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) joint guideline update. J Clin Oncol. 2021;39(9):1040–1091. doi:10.1200/JCO.20.03570.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–135. doi:10.1056/NEJMoa1504627.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639. doi:10.1056/NEJMoa1507643.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550. doi:10.1016/S0140-6736(15)01281-7.
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a Phase III, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–265. doi:10.1016/S0140-6736(16)32517-X.
   PubMed Web of Science ®Google Scholar
• Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, et al. Immunotherapy in non-small cell lung cancer: facts and hopes. Clin Cancer Res. 2019;25(15):4592–4602. doi:10.1158/1078-0432.CCR-18-1538.
   PubMed Web of Science ®Google Scholar
• Lu S, Stein JE, Rimm DL, Wang DW, Bell JM, Johnson DB, et al. Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: a systematic review and meta-analysis. JAMA Oncol. 2019;5(8):1195–1204. doi:10.1001/jamaoncol.2019.1549.
   PubMed Web of Science ®Google Scholar
• Jia Q, Wu W, Wang Y, Alexander PB, Sun C, Gong Z, et al. Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. Nat Commun. 2018;9(1):5361. doi:10.1038/s41467-018-07767-w.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–128. doi:10.1126/science.aaa1348.
   PubMed Web of Science ®Google Scholar
• Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52(1):17–35. doi:10.1016/j.immuni.2019.12.011.
   PubMed Web of Science ®Google Scholar
• Bianco A, Perrotta F, Barra G, Malapelle U, Rocco D, de Palma R. Prognostic factors and biomarkers of responses to immune checkpoint inhibitors in lung cancer. IJMS. 2019;20(19):4931. doi:10.3390/ijms20194931.
   Google Scholar
• Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557–4566. doi:10.1158/0008-5472.CAN-18-3962.
   PubMed Web of Science ®Google Scholar
• Gascón M, Isla D, Cruellas M, Gálvez EM, Lastra R, Ocáriz M, et al. Intratumoral versus circulating lymphoid cells as predictive biomarkers in lung cancer patients treated with immune checkpoint inhibitors: is the easiest path the best one? Cells. 2020;9(6):1525. doi:10.3390/cells9061525.
   Google Scholar
• Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–330. doi:10.1038/nature21349.
   PubMed Web of Science ®Google Scholar
• Iwahori K, Shintani Y, Funaki S, Yamamoto Y, Matsumoto M, Yoshida T, et al. Peripheral T cell cytotoxicity predicts T cell function in the tumor microenvironment. Sci Rep. 2019;9(1):2636. doi:10.1038/s41598-019-39345-5.
   PubMed Web of Science ®Google Scholar
• Pauken KE, Torchia JA, Chaudhri A, Sharpe AH, Freeman GJ. Emerging concepts in PD-1 checkpoint biology. Semin Immunol. 2021;52:101480. doi:10.1016/j.smim.2021.101480.
   PubMedGoogle Scholar
• Eisenhauer AE, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026.
   PubMed Web of Science ®Google Scholar
• Campbell JJ, Qin S, Unutmaz D, Soler D, Murphy KE, Hodge MR, et al. Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J Immunol. 2001;166(11):6477–6482. doi:10.4049/jimmunol.166.11.6477.
   PubMed Web of Science ®Google Scholar
• BD FACSCanto™ Software [accessed 2021 Apr 29]. Available from: https://www.bdbiosciences.com/en-eu/products/software/instrument-software/bd-facscanto-clinical-software/
   Google Scholar
• Kelsey JL, Whittemore AS, Evans AS, Thompson WD. Methods of sampling and estimation of sample size. In: Kelsey JL, Whittemore AS, Evans AS, Thompson WD, editors. Methods in Observational Epidemiology. New York (NY): Oxford University Press; 1996. p. 122–125.
   Google Scholar
• Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM, et al. Systemic immunity is required for effective cancer immunotherapy. Cell. 2017;168(3):487.e15–502.e15. doi:10.1016/j.cell.2016.12.022.
   Google Scholar
• Gascue A, Merino J, Paiva B. Flow cytometry. Hematol Oncol Clin North Am. 2018;32(5):765–775. doi:10.1016/j.hoc.2018.05.004.
   PubMedGoogle Scholar
• Kamphorst AO, Pillai RN, Yang S, Nasti TH, Akondy RS, Wieland A, et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc Natl Acad Sci U S A. 2017;114(19):4993–4998. doi:10.1073/pnas.1705327114.
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Veneziani M, Buti S, Gelsomino F, Squadrilli A, Bordi P, et al. Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab. Immunotherapy. 2018;10(8):681–694. doi:10.2217/imt-2017-0175.
   PubMedGoogle Scholar
• Mazzaschi G, Facchinetti F, Missale G, Canetti D, Madeddu D, Zecca A, et al. The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC. Lung Cancer. 2019;127:153–163. doi:10.1016/j.lungcan.2018.11.038.
   PubMed Web of Science ®Google Scholar
• Manjarrez-Orduño N, Menard LC, Kansal S, Fischer P, Kakrecha B, Jiang C, et al. Circulating T cell subpopulations correlate with immune responses at the tumor site and clinical response to PD1 inhibition in non-small cell lung cancer. Front Immunol. 2018;9:1613. doi:10.3389/fimmu.2018.01613.
   PubMed Web of Science ®Google Scholar
• Ottonello S, Genova C, Cossu I, Fontana V, Rijavec E, Rossi G, et al. Association between response to nivolumab treatment and peripheral blood lymphocyte subsets in patients with non-small cell lung cancer. Front Immunol. 2020;11:125. doi:10.3389/fimmu.2020.00125.
   Google Scholar
• Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545(7652):60–65. doi:10.1038/nature22079.
   PubMed Web of Science ®Google Scholar
• Dart SJ, Cook AM, Millward MJ, McDonnell AM, Chin WL, Hakeem MU, et al. Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors. Sci Rep. 2021;11(1):15312. doi:10.1038/s41598-021-93479-z.
   PubMedGoogle Scholar
• Kim CG, Kim KH, Pyo KH, Xin C-F, Hong MH, Ahn B-C, et al. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Ann Oncol. 2019;30(7):1104–1113. doi:10.1093/annonc/mdz123.
   PubMed Web of Science ®Google Scholar
• Kim CG, Hong MH, Kim KH, Seo IH, Ahn BC, Pyo KH, et al. Dynamic changes in circulating PD-1 + CD8 + T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer. Eur J Cancer. 2021;143:113–126. doi:10.1016/j.ejca.2020.10.028.
   PubMedGoogle Scholar
• de Goeje PL, Poncin M, Bezemer K, Kaijen-Lambers MEH, Groen HJM, Smit EF, et al. Induction of peripheral effector CD8 T-cell proliferation by combination of paclitaxel, carboplatin, and bevacizumab in non-small cell lung cancer patients. Clin Cancer Res. 2019;25(7):2219–2227. doi:10.1158/1078-0432.CCR-18-2243.
   PubMedGoogle Scholar
• Pluim D, Ros W, Miedema IHC, Miedema IHC, Beijnen JH, Schellens JHM. Multiparameter flow cytometry assay for quantification of immune cell subsets, PD-1 expression levels and PD-1 receptor occupancy by nivolumab and pembrolizumab. Cytometry A. 2019;95(10):1053–1065. doi:10.1002/cyto.a.23873.
   PubMedGoogle Scholar
• Zelba H, Bochem J, Pawelec G, Garbe C, Wistuba-Hamprecht K, Weide B. Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy. Cancer Immunol Immunother. 2018;67(12):1845–1851. doi:10.1007/s00262-018-2244-7.
   PubMedGoogle Scholar
• Youn JI, Park SM, Park S, Kim G, Lee H-J, Son J, et al. Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer. Sci Rep. 2020;10(1):9050. doi:10.1038/s41598-020-65666-x.
   PubMed Web of Science ®Google Scholar
• Hu W, Wang G, Huang D, Sui M, Xu Y. Cancer immunotherapy based on natural killer cells: current progress and new opportunities. Front Immunol. 2019;10:1205. doi:10.3389/fimmu.2019.01205.
   PubMed Web of Science ®Google Scholar
• Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Bourgeois-Daigneault MC, Trevino TN, et al. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. J Clin Invest. 2018;128(10):4654–4668. doi:10.1172/JCI99317.
   PubMed Web of Science ®Google Scholar
• Chen J, Chen Y, Feng F, Chen C, Zeng H, Wen S, et al. Programmed cell death protein-1/programmed death-ligand 1 blockade enhances the antitumor efficacy of adoptive cell therapy against non-small cell lung cancer. J Thorac Dis. 2018;10(12):6711–6721. doi:10.21037/jtd.2018.10.111.
   PubMedGoogle Scholar
• Oyer JL, Gitto SB, Altomare DA, Copik AJ. PD-L1 blockade enhances anti-tumor efficacy of NK cells. Oncoimmunology. 2018;7(11):e1509819. doi:10.1080/2162402X.2018.1509819.
   PubMed Web of Science ®Google Scholar
• Lin M, Luo H, Liang S, Chen J, Liu A, Niu L, et al. Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients. J Clin Invest. 2020;130(5):2560–2569. doi:10.1172/JCI132712.
   PubMedGoogle Scholar
• Kim HK, Heo MH, Lee HS, Sun J-M, Lee S-H, Ahn JS, et al. Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors. Cancer Chemother Pharmacol. 2017;80(3):591–598. doi:10.1007/s00280-017-3396-4.
   PubMed Web of Science ®Google Scholar
• Shaver KA, Croom-Perez TJ, Copik AJ. Natural killer cells: the linchpin for successful cancer immunotherapy. Front Immunol. 2021;12:679117. doi:10.3389/fimmu.2021.679117.
   PubMed Web of Science ®Google Scholar
• An HJ, Chon HJ, Kim C. Peripheral blood-based biomarkers for immune checkpoint inhibitors. IJMS. 2021;22(17):9414. doi:10.3390/ijms22179414.
   Google Scholar